AMH Test and Ovarian Reserve: What the Number Can and Cannot Tell You
Key Takeaways
AMH (anti-Müllerian hormone) is a blood test that estimates how many small follicles remain in the ovaries. It helps predict how the ovaries will respond to stimulation, but it does not measure egg quality and, on its own, it does not predict pregnancy or live birth. The result is read together with age and the antral follicle count, against the reference range of the laboratory that ran the test.
Key evidence: ASRM committee opinion on testing and interpreting measures of ovarian reserve ESHRE guideline: ovarian stimulation for IVF/ICSI, 2025 update AMH and the time to pregnancy in women aged 30 to 44 (JAMA 2017)
What Does an AMH Result Measure?
An AMH result often arrives before anyone has explained it, and a single number can feel like a verdict. It is not one. AMH (anti-Müllerian hormone) is made by the small follicles in the ovaries, so the blood level gives a rough estimate of how many of them are left. This is the quantitative side of ovarian reserve: how many eggs may be available, not how good they are.
The American Society for Reproductive Medicine (ASRM) describes AMH and the antral follicle count (AFC, the small follicles counted on a vaginal ultrasound) as the most useful tests of ovarian reserve. Both predict how many eggs a stimulation will produce, but they predict egg quality and live birth only weakly.
Is the Result Reliable?
AMH is usually steady enough across the menstrual cycle that it can be drawn on any day. Levels do vary slightly through the cycle, but not enough to justify timing the test to a cycle day. Two other things matter more than the cycle day.
- The laboratory. Assays differ, and reference ranges are specific to the method. Compare your value with the range printed on your own report, not with a number from the internet.
- Hormonal contraception. In a systematic review, AMH did not change in women using cyclical combined contraception for up to six months, but it was clearly lower in long-term users and recovered after stopping. A cross-sectional study of 27,125 women found mean AMH about 22% to 24% lower with the combined pill, the vaginal ring or the implant, about 15% lower with the progestin-only pill and about 7% lower with a hormonal IUD, and no difference with a copper IUD. Tell the doctor which method you use.
For these reasons the result is never read alone. It is placed next to your age and the follicle count on ultrasound.
How to Read a Low, Expected or High Result
Cut-off values depend on the laboratory and the age group, so the table below describes direction only, not numbers.
| Result for your age | What it usually suggests | What it can change |
|---|---|---|
| Low | Fewer small follicles remain | Stimulation planning and the conversation about timing |
| Expected for age | A typical response to stimulation | Usually no change to the usual plan |
| High | Many small follicles | Attention to over-response and OHSS risk; PCOS may be considered, but it is not diagnosed by AMH alone |
This is a guide to direction, not a diagnosis. Age remains the stronger predictor of whether treatment works.
What AMH Does in IVF Planning
AMH is used before a stimulation cycle. ESHRE recommends AFC or AMH to predict a low or high response to stimulation, while noting that the certainty of the evidence is very low. It helps the team choose the starting dose and the protocol and think ahead about the risk of ovarian hyperstimulation syndrome (OHSS).
Two limits are worth knowing.
- It does not predict a baby. ESHRE does not recommend AFC, AMH or other basal markers to predict pregnancy or live birth.
- Dosing by AMH is not a proven way to raise live birth. A Cochrane review found it uncertain whether choosing the gonadotropin dose from reserve markers increases live birth. It may lower the rate of moderate or severe OHSS, with low certainty.
Age, egg quality, sperm factors and the uterus carry the rest of the probability. The same logic applies to egg numbers, explained in How Many Eggs Are Usually Enough for IVF?
Does a Low AMH Mean You Cannot Get Pregnant?
No. In a prospective study of 750 women aged 30 to 44 without a history of infertility, those with low AMH (below 0.7 ng/mL) had a similar chance of conceiving within 6 and 12 cycles as women with normal values. A study of young, healthy women reached the same conclusion for fecundability.
Two cautions keep this honest. These cohorts were not women with a diagnosed fertility problem, and a very low value in someone with other risk factors deserves a proper conversation. ASRM also advises that a very low AMH should be used for counselling and not to refuse treatment.
In the same way, AMH is not a screening tool for premature ovarian insufficiency. The ESHRE guideline says AMH should not be the primary diagnostic test for it.
High AMH and PCOS
A high AMH reflects many small follicles, which is why it is linked to polycystic ovary syndrome (PCOS). The international PCOS guideline allows AMH to be used in adults instead of the ultrasound follicle criterion, but not as a single test, and it asks for thresholds that are specific to the assay and the population. Cycle pattern and signs of high androgen levels still count. Read more in our article on polycystic ovary syndrome.
Frequently Asked Questions for Dr. Aksoy
Does the AMH result change when it is repeated, and when do you ask for a repeat test?
Yes. AMH can change over time, partly through normal biological variation and partly because laboratories use different methods. Hormonal contraceptives can lower it temporarily. I always read the result together with the patient’s age and the antral follicle count on ultrasound. If AMH is much lower than expected, clearly different from a previous result, or does not fit the ultrasound, I repeat it, preferably in the same laboratory. When a hormonal contraceptive is involved, re-evaluation after about 2 to 3 months can be considered in suitable patients. Repeating AMH again and again to follow small changes has no clinical benefit.
What do you think when AMH is high, and do you change the IVF protocol?
A high AMH usually suggests many small follicles. It can be linked to PCOS, but it does not make the diagnosis on its own: cycle pattern, signs of high androgens and, when needed, the ultrasound all matter. When IVF is planned, a high AMH matters to me mainly because of the risk of over-response and OHSS. In these patients I usually prefer a GnRH antagonist protocol with lower, individually adjusted starting doses of gonadotropin. If a high response develops, I aim to reduce OHSS risk with a GnRH agonist trigger and a strategy of freezing all embryos.
What do you advise when AMH is low but the patient does not want a child yet?
First I explain that a low AMH does not mean she cannot get pregnant. AMH tells us more about egg quantity and the expected response to stimulation. It does not show egg quality or the chance of natural pregnancy on its own. I would not give the same advice to a 28-year-old with regular cycles and a low AMH as to a 39-year-old. Age, antral follicle count, how long she wants to wait, previous ovarian surgery and a family history of early menopause change my advice the most. After 35, if pregnancy will be delayed by several years and reserve is also low, I discuss timing more seriously. But I would not tell a young woman that IVF must start now only because her AMH is low. My aim is not to frighten the patient but to help her plan at the right time.
Final Thoughts
AMH is a useful number for planning stimulation and for spotting a likely high or low response. It is a poor number for predicting a pregnancy. Ask for it to be read alongside your age, your ultrasound and your history, and ask which reference range the laboratory used. If the value surprises you, a calm second look is often more helpful than a second test.
Continue Reading
- Pre-IVF testing
- How Many Eggs Are Usually Enough for IVF?
- Polycystic ovary syndrome: diagnosis, treatment and fertility
- Premature ovarian insufficiency
Sources
- Practice Committee of the American Society for Reproductive Medicine. Testing and interpreting measures of ovarian reserve: a committee opinion. Fertil Steril 2020;114(6):1151–1157.
- Ata B, Bosch E, Broer S, et al. ESHRE guideline: ovarian stimulation for IVF/ICSI: an update in 2025. Hum Reprod 2026;41(4):498–514.
- Panay N, Anderson RA, Bennie A, et al. Evidence-based guideline: premature ovarian insufficiency. Hum Reprod Open 2024;2024(4):hoae065.
- Teede HJ, Tay CT, Laven JJE, et al. Recommendations from the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Hum Reprod 2023;38(9):1655–1679.
- Ngwenya O, Lensen SF, Vail A, Mol BWJ, Broekmans FJ, Wilkinson J. Individualised gonadotropin dose selection using markers of ovarian reserve for women undergoing in vitro fertilisation plus intracytoplasmic sperm injection (IVF/ICSI). Cochrane Database Syst Rev 2024;1:CD012693.
- Steiner AZ, Pritchard D, Stanczyk FZ, et al. Association between biomarkers of ovarian reserve and infertility among older women of reproductive age. JAMA 2017;318(14):1367–1376.
- Hagen CP, Vestergaard S, Juul A, Skakkebæk NE. Low concentration of circulating antimüllerian hormone is not predictive of reduced fecundability in young healthy women: a prospective cohort study. Fertil Steril 2012;98(6):1602–1608.
- Kissell KA, Danaher MR, Schisterman EF, Wactawski-Wende J. Biological variability in serum anti-Müllerian hormone throughout the menstrual cycle in ovulatory and sporadic anovulatory cycles in eumenorrheic women. Hum Reprod 2014;29(8):1764–1772.
- Amer SAKS, James C, Al-Hussaini TK, Mohamed AA. Assessment of circulating anti-Müllerian hormone in women using hormonal contraception: a systematic review. J Womens Health 2020;29(1):100–110.
- Hariton E, Shirazi TN, Douglas NC, Hershlag A, Briggs SF. Anti-Müllerian hormone levels among contraceptive users: evidence from a cross-sectional cohort of 27,125 individuals. Am J Obstet Gynecol 2021;225(5):515.e1–515.e10.
Add as a Preferred Source on Google
You can add draksoyivf.com as one of your preferred health information sources on Google.
The content has been created by Dr. Senai Aksoy and medically approved.